


CANCER DU SEIN HER 2 METASTATIQUE

Prise en charge de la patiente âgée

UCOG 06/02/2025


Dr Edwina GIRARD, GHBS LORIENT

CANCER DU SEIN HER 2




Cellule tumorale

CANCER DU SEIN HER 2




Cellule tumorale

CANCER DU SEIN HER 2




HER2 négatif




© 2020
HER2 positif
(surexpression)

CANCER DU SEIN HER 2



Cellule tumorale

CANCER DU SEIN HER 2



Cellule tumorale

CANCER DU SEIN HER 2

RECEPTEURS
HORMONAUX



Absence de récepteurs hormonaux
RH négatifs




Présence de récepteurs hormonaux
RH positifs


© 2020

CANCER DU SEIN HER 2

2 types de cancer « HER 2 »



HER 2 positif avec RH
négatifs




HER 2 positif avec RH
positifs

CANCER DU SEIN HER 2 M+

Base ESME :
22 000 patientes M+
2008-2016

Overall survival in the three subcohorts with number at risk and 95% CI




Age (years) at diagnosis of MBC

Median (Q1–Q3 range)


Age groups

<45 years	3050 (13.8)	1556 (11.4)	777 (19.3)	647 (21.8)
45–65 years	10,990 (49.7)	6782 (49.7)	2158 (53.7)	1492 (50.4)
>65 years	8069 (36.5)	5318 (38.9)	1082 (27.0)	824 (27.8)


PREMIERE LIGNE DE CHIMIOTHERAPIE




PREMIERE LIGNE DE CHIMIOOTHERAPIE




PREMIERE LIGNE DE CHIMIOOTHERAPIE




PREMIERE LIGNE DE CHIMIOOTHERAPIE



PREMIERE LIGNE DE CHIMIOOTHERAPIE



PREMIERE LIGNE DE CHIMIOOTHERAPIE



Analyse en sous-groupe : vs TAXOL HERCEPTINE seul

Age				0.27
<65 yr	681		0.70 (0.56–0.87)	
≥65 yr	127		0.53 (0.31–0.90)	
Age				0.84
<75 yr	789		0.68 (0.55–0.83)	
≥75 yr	19		0.85 (0.26–2.73)	

CLEOPATRA, NEJM 2015

PREMIERE LIGNE DE CHIMIOETHERAPIE

TOXICITES:

TAXOL : 1/semaine pendant 24 semaines

- Neutropénie dont neutropénie fébrile plutôt modérée
- Asthénie
- Alopécie prévenue par casque
- Paresthésies
- Syndrome main-pied
- Toxicité unguéale
- Diarrhées

PHESGO (Trastuzumab/Pertuzumab) 1/3semaines en SC :

- Cardio-toxicité => surveillance baisse FE
- Allergie (1^{ère} cure avec une nuit en HDS)
- Diarrhées
- Prurit

PREMIERE LIGNE DE CHIMIOETHERAPIE

TOXICITES:

TAXOL : 1/semaine pendant 24 semaines

- Neutropénie dont neutropénie fébrile plutôt modérée
- Asthénie
- Alopécie prévenue par casque
- Paresthésies
- Syndrome main-pied
- Toxicité unguéale
- Diarrhées

PHESGO (Trastuzumab/Pertuzumab) 1/3semaines en SC:

- Cardio-toxicité => surveillance baisse FE
- Allergie (1^{ère} cure avec une nuit en HDS)
- Diarrhées
- Prurit



HORMONOTHERAPIE : 1 cp per os en continu:

- Syndrome Climatérique

Anti-CDK4/6 PALBOCICLIB 1 cp 3S/4S:





- Neutropénie : généralement non fébrile
- Asthénie

OPTION PREMIERE LIGNE CHEZ RH+ : CT





PERTAIN, JCO 2018

OPTION PREMIERE LIGNE CHEZ RH+ : CT



PERTAIN, JCO 2018

OPTION PREMIERE LIGNE CHEZ RH+ : CT



PERTAIN, JCO 2018

Table 1. Baseline Patient Demographics and Clinical Characteristics

Characteristic	Trastuzumab + Anastrozole (n = 103)		Anastrozole Alone (n = 104)	
	No. of Patients	%	No. of Patients	%
Age, years				
Median	56		54	
Range	31-85		27-77	

Age category, years

< 65	172	108	0.66	(0.45 to 0.97)
≥ 65	86	58	0.66	(0.39 to 1.12)
< 75	210	134	0.65	(0.47 to 0.92)
≥ 75	48	32	0.65	(0.31 to 1.35)

